T4	Subject 20 30	2 patients
T5	Effect 53 87	CD8+ cutaneous lymphoproliferative
T6	Treatment 119 144	efalizumab and infliximab
T8	Population 20 21	2
T9	Drug 119 129	efalizumab
T10	Drug 134 144	infliximab
T7	Adverse_event 35 44	developed
T11	Combination 130 133	and
E1	Adverse_event:T7 
E2	Combination:T11 arg:T9 arg2:T10